Phase III DAPA-HF trial of Farxiga shows efficacy in heart failure.- AstraZeneca

New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their background therapy (i.e. other medications for heart failure). Farxiga was evaluated in patients who were receiving a broad range of pharmacological treatments, device therapies and cardiac resynchronisation therapy for HFrEF. A consistent reduction in the primary outcome was observed across all these treatment subgroups. The results were made available at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) and were published in the European Heart Journal.See: "Effects of dapagliflozin in DAPA-HF according to background heart failure therapy" Kieran F Docherty et al. European Heart Journal, ehaa183, Published: 28 March 2020 https://doi.org/10.1093/eurheartj/ehaa183